jRCT2080221451未知1 期
Phase I Clinical Study of RG7167 in Patients with Advanced Solid Tumors
试验速览
- 阶段
- 1 期
- 入组人数
- 36
- 主要终点
- -
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 干预模型
- Single-site unblinded study
入排标准
- 年龄范围
- 20age old over 至 No limit（—）
- 性别
- All
入选标准
- •Histologically or cytologically confirmed solid tumor
- •Advanced cancer that did not respond to the standard therapy or for which a standard therapy has not been established
- •PS of 0 to 2
排除标准
- •Patients in whom an adverse reaction to the previous treatment persists at Grade 2 or higher
- •Patients with metastasis to the central nervous system that is accompanied by symptoms or requires treatment
- •Clinically significant inflammatory condition is observed on the ocular surface
- •Patients who have been treated with a drug targeting MEK in the past
结局指标
主要结局
-
MTD, Safety, Pharmacokinetics NCI-CTCAE ver. 3.0
次要结局
未报告次要终点
研究者
相似试验
未知
1 期
Phase I Clinical Study of RG7167 in Patients with Advanced Solid TumorsJPRN-jRCT2080221451Chugai Pharmaceutical Co., Ltd.36
未知
1 期
Phase I Clinical Study of RG7304 in Patients with Advanced Solid TumorsjRCT2080221452Chugai Pharmaceutical Co., Ltd.30
未知
1 期
Phase I Clinical Study of RG7304 in Patients with Advanced Solid TumorsJPRN-jRCT2080221452Chugai Pharmaceutical Co., Ltd.30
已完成
1 期
Phase I study of RO6874281 in patients with advanced solid tumorsjRCT2080224653Chugai Pharmaceutical Co., Ltd.18
招募中
不适用
A Phase 1 study of GSK5764227 in participants with advanced solid tumorsjRCT2031240381GlaxoSmithKline K.K.15